Xenon Pharmaceuticals (XENE) Income from Continuing Operations (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Income from Continuing Operations of 102302000.0 for Q1 2026, down 57.27% year-over-year from 239437183.15 in Q1 2025, and down 142.17% quarter-over-quarter from 242606000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Income from Continuing Operations data on file, last reported at 102302000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 102302000.0, down 57.27% year-over-year; the trailing twelve-month figure through Mar 2026 was 35298000.0 (up 86.24% YoY), and the FY2025 annual result was 1957000.0, up 100.82% from the prior year.
- Income from Continuing Operations eased to 102302000.0 in Q1 2026 per XENE's latest filing, from 242606000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 242606000.0 in Q4 2025 and troughed at 102302000.0 in Q1 2026.
- A 5-year average of 37371647.06 and a median of 47931000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slumped 140.53% in 2022, then jumped 443.27% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 33475000.0 in 2022, then declined by 9.18% to 36549000.0 in 2023, then sank by 93.37% to 70676000.0 in 2024, then jumped by 443.27% to 242606000.0 in 2025, then slumped by 142.17% to 102302000.0 in 2026.
- Business Quant data shows XENE's Income from Continuing Operations at 102302000.0 in Q1 2026, 242606000.0 in Q4 2025, and 90896000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | -102.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.30 Mn |
| Dec 31, 2025 | 242.61 Mn |
| Sep 30, 2025 | -90.90 Mn |
| Jun 30, 2025 | -84.71 Mn |
| Mar 31, 2025 | -65.05 Mn |
| Dec 31, 2024 | -70.68 Mn |
| Sep 30, 2024 | -62.79 Mn |
| Jun 30, 2024 | -57.92 Mn |
| Mar 31, 2024 | -47.93 Mn |
| Dec 31, 2023 | -36.55 Mn |
| Sep 30, 2023 | -48.46 Mn |
| Jun 30, 2023 | -47.46 Mn |
| Mar 31, 2023 | -41.73 Mn |
| Dec 31, 2022 | -33.48 Mn |
| Sep 30, 2022 | -37.15 Mn |
| Jun 30, 2022 | -31.16 Mn |
| Mar 31, 2022 | -19.67 Mn |
| Dec 31, 2021 | -25.56 Mn |
| Sep 30, 2021 | -15.45 Mn |
| Jun 30, 2021 | -22.11 Mn |